Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for RARE
Across the 12 sessions after earlier RARE headlines, the stock closed higher 7 times and lower 5 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RARE | SPY |
|---|---|---|---|
| Jan 12, 2026 | Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference | +8.3% | +0.2% |
| Jan 8, 2026 | Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference | -4.1% | -0.0% |
| Dec 31, 2025 | Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) | +1.0% | -0.7% |
| Dec 29, 2025 | Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta | -42.3% | -0.4% |
| Dec 22, 2025 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +3.7% | +0.6% |
| Nov 25, 2025 | Ultragenyx to Participate in Investor Conferences in December | +2.3% | +0.9% |
Quantisnow market dataNASDAQ
RARE
Ultragenyx Pharmaceutical Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for RARE
Full RARE profile on Quantisnow Follow RARE and get a push notification the moment its next story breaks.